Anjali Gupta

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT
    Anjali K Gupta
    Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Int J Radiat Oncol Biol Phys 74:928-33. 2009
  2. ncbi request reprint Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Clin Cancer Res 8:885-92. 2002
  3. ncbi request reprint Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
  4. pmc The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 9:271-8. 2007
  5. ncbi request reprint HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo
    Anjali K Gupta
    Department of Radiation and Biostatistics, University of Pennsylvania, Philadelphia 19104, USA
    Cancer Res 65:8256-65. 2005
  6. ncbi request reprint Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 56:846-53. 2003
  7. ncbi request reprint C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblasts
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Cancer Biol Ther 2:73-5. 2003
  8. ncbi request reprint Signaling inhibition with radiation in colorectal cancer: clinical trials
    W Gillies McKenna
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19004, USA
    Semin Oncol 30:56-67. 2003
  9. ncbi request reprint Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
    John P Plastaras
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 67:9443-54. 2007
  10. ncbi request reprint Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy
    Nabendu Pore
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:9252-9. 2006

Research Grants

Detail Information

Publications22

  1. pmc Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT
    Anjali K Gupta
    Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Int J Radiat Oncol Biol Phys 74:928-33. 2009
    ..We are in the process of starting a clinical trial in H&N cancer patients using nelfinavir (NFV) (which inhibits Akt) and it would be important to know the effect of HPV on radiation response +/- NFV...
  2. ncbi request reprint Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Clin Cancer Res 8:885-92. 2002
    ..We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome...
  3. ncbi request reprint Signaling pathways in NSCLC as a predictor of outcome and response to therapy
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lung 182:151-62. 2004
    ..This further suggests that Akt might be a useful target for sensitization of NSCLC to radiation...
  4. pmc The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 9:271-8. 2007
    ..These findings may have important implications in understanding how nelfinavir may increase radiation sensitivity and also result in downregulation of the PI3K/Akt pathway...
  5. ncbi request reprint HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo
    Anjali K Gupta
    Department of Radiation and Biostatistics, University of Pennsylvania, Philadelphia 19104, USA
    Cancer Res 65:8256-65. 2005
    ..Because there is abundant safety data on HPIs accumulated in thousands of HIV patients over the last 5 years, these agents are excellent candidates to be tested as radiation sensitizers in clinical trials...
  6. ncbi request reprint Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 56:846-53. 2003
    ..Inhibition of PI3K by LY294002 can synergistically enhance radiation efficacy. This acts as a proof of principle that inhibition of the Ras to PI3K pathway could be useful clinically...
  7. ncbi request reprint C-Raf-1 protein kinase is not essential for Ras transformation of mouse embryo fibroblasts
    Anjali K Gupta
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6072, USA
    Cancer Biol Ther 2:73-5. 2003
    ..Both cell lines were however able to form tumors in nude mice. These results suggest that c-Raf-1 is not required for Ras transformation in this system...
  8. ncbi request reprint Signaling inhibition with radiation in colorectal cancer: clinical trials
    W Gillies McKenna
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19004, USA
    Semin Oncol 30:56-67. 2003
    ..Identifying a common signal for EGFR, Ras, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control...
  9. ncbi request reprint Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation
    John P Plastaras
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 67:9443-54. 2007
    ..This study establishes a foundation for clinical testing of sequential fractionated radiation followed by sorafenib in gastrointestinal and other malignancies...
  10. ncbi request reprint Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy
    Nabendu Pore
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:9252-9. 2006
    ..These data support the use of nelfinavir in combination with radiation in future clinical trials...
  11. ncbi request reprint EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms
    Nabendu Pore
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:3197-204. 2006
    ..Similar results were obtained with erlotinib in SQ20B and gefitinib in HSC3 squamous carcinoma cells. These results indicate that there are at least two separate mechanisms by which EGFR inhibitors decrease VEGF expression...
  12. pmc Signaling pathways in adenoid cystic cancers: implications for treatment
    Anjali K Gupta
    Department of Radiation Oncology, University of Iowa Hospital and Clinics, Iowa City, IA, USA
    Cancer Biol Ther 8:1947-51. 2009
    ..Both P-Akt and P-MAPK were inhibited with NFV in ACC3 cells and this resulted in growth inhibition and clonogenic death. In patients where re-irradiation or further surgery is not an option, a trial of NFV may be warranted...
  13. ncbi request reprint Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir
    Zibin Jiang
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 67:4467-73. 2007
    ..These results support the clinical investigation of nelfinavir in combination with radiation and temozolomide in future clinical trials for patients with glioblastomas...
  14. ncbi request reprint The RAS signal transduction pathway and its role in radiation sensitivity
    W Gillies McKenna
    Departments of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19103, USA
    Oncogene 22:5866-75. 2003
    ..Identifying a common signal for EGFR, RAS, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control...
  15. ncbi request reprint Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans
    John P Plastaras
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 7:628-35. 2008
    ....
  16. pmc HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells
    Nabendu Pore
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neoplasia 8:889-95. 2006
    ..Our results support further research into these protease inhibitors for use in future clinical trials for patients with glioblastoma multiformes...
  17. ncbi request reprint Bortezomib sensitizes human head and neck carcinoma cells SQ20B to radiation
    Charles N Weber
    Department of Radiation Oncology, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA 19104, USA
    Cancer Biol Ther 6:156-9. 2007
    ..The dose of bortezomib is also 2 logs less as a sensitizer than that required for single agent efficacy. Further studies should be done to explore this model in vivo...
  18. pmc Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
    Gary D Kao
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 282:21206-12. 2007
    ..These results together support a direct link between Akt activation, repair of DNA damage, and radioresistance in glioblastoma. Targeting the PI3K/Akt pathway may modulate DNA repair to improve the efficacy of radiation therapy...
  19. ncbi request reprint Farnesyltransferase inhibitors as radiation sensitizers
    W Gillies McKenna
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104, USA
    Semin Radiat Oncol 12:27-32. 2002
    ..Additional clinical trials should shed light on the potential of this and other farnesyltransferase inhibitors to serve as radiosensitizers and may identify molecular markers that could predict a response to these agents...
  20. ncbi request reprint The influence of Ras pathway signaling on tumor radiosensitivity
    In Ah Kim
    Department of Radiation Oncology, 185 John Morgan Bldg, 37th and Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104 6072
    Cancer Metastasis Rev 23:227-36. 2004
    ..We will also point out new means of studying the contribution of Ras and Ras pathway components that could contribute to defining new targets for inhibition in the context of radiation therapy...
  21. ncbi request reprint A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer
    Neil E Martin
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 10:5447-54. 2004
    ....
  22. ncbi request reprint Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations
    Thomas B Brunner
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 6072, USA
    Cancer Res 63:5656-68. 2003
    ..We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs...

Research Grants2

  1. Radiosensitization with the HIV protease inhibior Nelfinavir in NSCLC
    Anjali Gupta; Fiscal Year: 2007
    ..Specific Aim 3. To investigate in vitro the molecular mechanisms by which NFV results in sensitization. ..